Dosage & Administration Drug label Prior authorization Financial assistance

Humira

(adalimumab)

0.1 ML adalimumab 100 MG/ML Prefilled Syringe [Humira]0.2 ML adalimumab 100 MG/ML Prefilled Syringe [Humira]

View 7 more

BLACK BOX WARNING

Dosage & administration

* Administer by subcutaneous injection

Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis ( 2.1):

* Adults: 40 mg every other week.
● Some patients with RA not receiving methotrexate may benefit from increasing the dosage to 40 mg every week or 80 mg every other week.

Juvenile Idiopathic Arthritis or Pediatric Uveitis ( 2.2):

Pediatric Weight 2 Years of Age and Older	Recommended Dosage
10 kg (22 lbs) to less than 15 kg (33 lbs)	10 mg every other week
15 kg (33 lbs) to less than 30 kg (66 lbs)	20 mg every other week
30 kg (66 lbs) and greater	40 mg every other week

Crohn's Disease ( 2.3):

* Adults: 160 mg on Day 1 (given in one day or split over two consecutive days); 80 mg on Day 15; and 40 mg every other week starting on Day 29.

* Pediatric Patients 6 Years of Age and Older:

Pediatric Weight	Recommended Dosage
	Days 1 and 15	Starting on Day 29
17 kg (37 lbs) to less than 40 kg (88 lbs)	Day 1: 80 mg Day 15: 40 mg	20 mg every other week
40 kg (88 lbs) and greater	Day 1: 160 mg (single dose or split over two consecutive days) Day 15: 80 mg	40 mg every other week

Ulcerative Colitis ( 2.4):

* Adults: 160 mg on Day 1 (given in one day or split over two consecutive days), 80 mg on Day 15 and 40 mg every other week starting on Day 29. Discontinue in patients without evidence of clinical remission by eight weeks (Day 57).

* Pediatric Patients 5 Years of Age and Older:

Pediatric Weight	Recommended Dosage
	Days 1 through 15	Starting on Day 29*
20 kg (44 lbs) to less than 40 kg (88 lbs)	Day 1: 80 mg Day 8: 40 mg Day 15: 40 mg	40 mg every other week or 20 mg every week
40 kg (88 lbs) and greater	Day 1: 160 mg (single dose or split over two consecutive days) Day 8: 80 mg Day 15: 80 mg	80 mg every other week or 40 mg every week
* Continue the recommended pediatric dosage in patients who turn 18 years of age and who are well-controlled on their HUMIRA regimen.

Plaque Psoriasis or Adult Uveitis ( 2.5):

* Adults: 80 mg initial dose, followed by 40 mg every other week starting one week after initial dose.

Hidradenitis Suppurativa ( 2.6):

* Adults:
○ Day 1: 160 mg (given in one day or split over two consecutive days)
○ Day 15: 80 mg
○ Day 29 and subsequent doses: 40 mg every week or 80 mg every other week

* Adolescents 12 years of age and older:

Adolescent Weight	Recommended Dosage
30 kg (66 lbs) to less than 60 kg (132 lbs)	Day 1: 80 mg Day 8 and subsequent doses: 40 mg every other week
60 kg (132 lbs) and greater	Day 1: 160 mg (given in one day or split over two consecutive days) Day 15: 80 mg Day 29 and subsequent doses: 40 mg every week or 80 mg every other week

Humira prescribing information

Have more Humira questions?

Submit MSL Request

Learn More

Need to report a Humira issue?

ONLINE FORMReport adverse event

Learn More

prior authorization

Humira Prior authorization resources

NOT PROVIDED BY BRANDComplete Letter of Medical Necessity

NOT PROVIDED BY BRANDCoverage Authorization Request

NOT PROVIDED BY BRANDComplete Coverage Authorization appeals

Dermatology Enrollment Form - Adults

Gastroenterology Enrollment Form - Adults

Rheumatology Enrollment Form - Adults

Dermatology Enrollment Form - Pediatrics

Gastroenterology Enrollment Form - Pediatrics

Rheumatology Enrollment Form - Pediatrics

NOT PROVIDED BY BRANDCoverage Authorization Appeal

Learn More

Benefits investigation

Dermatology Enrollment Form - Adults

Gastroenterology Enrollment Form - Adults

Rheumatology Enrollment Form - Adults

Dermatology Enrollment Form - Pediatrics

Gastroenterology Enrollment Form - Pediatrics

Rheumatology Enrollment Form - Pediatrics

Learn More

Reimbursement help (FRM)

Receive Assistance from an FRM Regarding Reimbursement Information

Learn More

financial assistance

Humira Financial assistance options

Co-pay savings program

commercial only

Enroll in patient savings program

Learn More

Overview

Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)

Patient benefit

A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max

Patient eligibility

Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
May never be used with government insurance

How to sign up

Cards may be downloadable digital cards or hard copies
Some pharmacos offer debit cards with pre-loaded copay benefit
Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form

Bridge program

commercial only

Learn More

Overview

Provide patient immediate access to therapy during an insurance delay (typically new starts; some may cover change in insurance)
Limited time/ fill (typically 7-30 days; some may offer additional fill for continued delay up to certain limit)

Patient benefit

100% free (outside of insurance)

Patient eligibility

HCP must enroll patient
May be limited to commercially insured patients (i.e., no government beneficiaries); some programs may allow government beneficiaries

How to sign up

Typically HCP assisted enrollment (via form)

Foundation programs

under insured

no insurance

goverment insurance

65+

Abbvie Patient Assistance Program Application - English

Abbvie Patient Assistance Program Application - Spanish

Learn More

Overview

Charitable 501(c)(3) organizations provide direct cost-sharing and other support (e.g., travel, counseling) through disease-state funds to indigent patients on first-come first-served basis
These organizations may receive financial contributions from drug manaufacturers for particular disease-state funds that cannot provide funds directly to patients - the foundation must be independent/unaligned

Patient benefit

Patients apply for grants that cover a portion (or all) of their out-of-pocket costs (deductibles and co-pays) until the grant is exhausted

Patient eligibility

Patients must apply and meet eligibility criteria including income level (typically a multiple of federal poverty line), specific diagnosis, insurance status, etc.

How to sign up

Patients submit proof of out-of-pocket drug costs to charities for reimbursement